HomeCompareOPGX vs ABBV

OPGX vs ABBV: Dividend Comparison 2026

OPGX yields 666666.67% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OPGX wins by $8.275235618773884e+34M in total portfolio value
10 years
OPGX
OPGX
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275235618773884e+34M
Annual income
$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00
Full OPGX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — OPGX vs ABBV

📍 OPGX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOPGXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OPGX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OPGX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OPGX
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, OPGX beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OPGX + ABBV for your $10,000?

OPGX: 50%ABBV: 50%
100% ABBV50/50100% OPGX
Portfolio after 10yr
$4.137617809386942e+34M
Annual income
$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

OPGX
No analyst data
Altman Z
-27.1
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OPGX buys
0
ABBV buys
0
No recent congressional trades found for OPGX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOPGXABBV
Forward yield666666.67%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$8.275235618773884e+34M$102.3K
Annual income after 10y$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$8.275075881065991e+34M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OPGX vs ABBV ($10,000, DRIP)

YearOPGX PortfolioOPGX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$66,677,367$66,666,666.67$11,550$430.00+$66.67MOPGX
2$415,506,651,117$415,435,306,334.37$13,472$627.96+$415506.64MOPGX
3$2,419,908,598,386,268$2,419,464,006,269,573.00$15,906$926.08+$2419908598.37MOPGX
4$13,171,697,643,084,456,000$13,169,108,340,884,183,000.00$19,071$1,382.55+$13171697643084.44MOPGX
5$67,004,927,492,790,120,000,000$66,990,833,776,312,020,000,000.00$23,302$2,095.81+$67004927492790120.00MOPGX
6$318,562,277,003,514,840,000,000,000$318,490,581,731,097,560,000,000,000.00$29,150$3,237.93+$318562277003514871808.00MOPGX
7$1,415,484,168,853,553,000,000,000,000,000$1,415,143,307,217,159,200,000,000,000,000.00$37,536$5,121.41+$1.415484168853553e+24MOPGX
8$5,878,130,573,362,507,000,000,000,000,000,000$5,876,616,005,301,833,000,000,000,000,000,000.00$50,079$8,338.38+$5.878130573362507e+27MOPGX
9$22,813,793,009,840,743,000,000,000,000,000,000,000$22,807,503,410,127,248,000,000,000,000,000,000,000.00$69,753$14,065.80+$2.2813793009840744e+31MOPGX
10$82,752,356,187,738,840,000,000,000,000,000,000,000,000$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$8.275235618773884e+34MOPGX

OPGX vs ABBV: Complete Analysis 2026

OPGXStock

Optigenex Inc. engages in the manufacture and sale of healthy age management and beauty care products. The company offers AC-11, a powdered and bioactive rainforest plant extract that helps the body to repair sun and environmental stress-related damage to DNA, and slow down the process of skin aging. It serves manufacturers, distributors, and retailers worldwide in the dietary supplement, as well as anti-aging topical skin care, cosmetic, and cosmeceutical market categories. The company is based in Melissa, Texas.

Full OPGX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this OPGX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OPGX vs SCHDOPGX vs JEPIOPGX vs OOPGX vs KOOPGX vs MAINOPGX vs JNJOPGX vs MRKOPGX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.